The Latest in Colorectal Cancer Research

Welcome!

Part of Fight Colorectal Cancer’s Monthly Patient Webinar Series

Our webinar will begin shortly

www.FightColorectalCancer.org877-427-2111

Fight Colorectal Cancer

1. Tonight’s speaker: Dr. Richard Goldberg, MD

2. Archived webinars: Link.FightCRC.org/Webinars

3. Follow up survey to come via email. Get a free Blue Star of Hope pin when you tell us how we did tonight.

4. Ask a question in the panel on the right side of your screen and look for hyperlinks during throughout the presentation.

5. Or call the Fight Colorectal Cancer Answer Line at 877-427-2111

Fight Colorectal CancerDisclaimer

The information and services provided by Fight Colorectal Cancer are for general informational purposes only.

The information and services are not intended to be substitutes for professional medical advice, diagnosis, or treatment.

If you are ill, or suspect that you are ill, see a doctor immediately. In an emergency, call 911 or go to the nearest emergency room.

Fight Colorectal Cancer never recommends or endorses any specific physicians, products or treatments for any condition.

Fight Colorectal CancerMarch 2013 Events

March 1: Times Square Kick Off

March 18-20: Call-on Congress Registration closes on Feb. 22nd! www.FightColorectalCancer.org

March 20: Congressional Call-In Unite behind a cure! Join our one-day phone blitz to Congress

Website: www.ccalliance.orgHelpline: (877) 422-2030

My CCA Support Online Community: www.myccasupport.org

Dr. Richard Goldberg, MDPhysician-in-Chief

Professor of MedicineThe Klotz Family Chair in Cancer Research

Associate Director of OutreachThe Ohio State University Comprehensive Cancer Center

Richard M Goldberg M.D.Klotz Family Chair in Cancer Research

Professor and James Cancer Hospital Physician-in-ChiefThe Ohio State University

Cancer of the Colon and Rectum: A Decade of Progress

The Ohio State University Comprehensive Cancer Center –

Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Trends in Incidence Rates: 1975-2008

Seigel, Cancer Statistics, 2012, CA Cancer J Clin.,62:10-29, 2012

US Death Rates in Men & Women:1975-200857,100 in 2003 & 51,690 in 2012

Seigel, Cancer Statistics, 2012, CA Cancer J Clin.,62:10-29, 2012

The Genetics of Colorectal Cancer:Henry Lynch

13% <1% 85%

FAP Sporadic

MIN (MSI+)(Microsatellite Instability)

CIN (Chromosome Instability)

Lynch Sx Sporadic MSI(+)

Germline Mutation MMR genesMLH1, MSH2, MSH6 & PMS2

•Epigenetic silencing of MLH1 by hypermethylation of its promoter region

Colorectal Cancer: Genetics

Acquired APC, p53, DCC, kras, LOH,...

Germline Mutation APC

Revised Lynch Syndrome Screening Criteria

(Amsterdam criteria II) > 3 relatives with an HNPCC-associated cancer

(CRC, cancer of the endometrium, small bowel, ureter, or renal pelvis)

One should be a first-degree relative of the other 2 At least 2 successive generations should be affected At least 1 should be diagnosed before age 50 Familial adenomatous polyposis should be excluded

in the CRC case(s) if any Tumors should be verified by pathological exam

Vasen, Gastroenterology, 116: 1453-6, 1999

Patient & Family Implications: Lynch Syndrome

MSH2 MSH6

Screening for the Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer)

Hampel H, Frankel W, Martin E, Arnold M, Khanduja K, Kuebler P, Nakagawa H, Sotamaa K, Prior T, Westman J, Panescu J, Fix D, Lockman J, Comeras I, and

de la Chapelle A.

N Engl J MedMedVolume 352:1851-1860, 2005

Heather Hampel Albert de la Chapelle

Potential Impact

Columbus Project: 44 of 1600 screened had Lynch Syndrome 50% diagnosed over age 50 25% met neither Amsterdam or Bethesda criteria

Ohio Colorectal Cancer Prevention Initiative Nationally

143,460 new cases of CRC in the US in 2013 4,016 have Lynch syndrome (2.8%) 12,050 of their relatives have LS (~3 per proband)

Total of 15,816 individuals who could be diagnosed with Lynch Syndrome with universal screening

American Cancer Society Facts & Figures

The Cancer Genome Atlas NetworkNature 487: 330-337, 2012

Genomics:

Comprehensive Molecular Characterization of Human Colon

and Rectal Cancer

Raju Kucherlapati

Methods and Key Findings

Methods: Whole genome sequencing of 276 colorectal tumors Exome sequence, DNA copy number, promotor

methylation, messenger and micro RNA expression

Key Findings 16% hypermutated; 75% MSI-H Colon and rectal cancers share similar patterns of

genomic alteration 24 genes significantly mutated:

Expected: APC, TP53, SMAD4, PIK3CA, KRAS Unexpected: ARID1A, SOX9, FAM123B, ERBB2

Potential new targets: ERBB2, IGF2

Genomics: Cancer Genome Atlas

Significance

“While it may take years to translate this foundational genetic data on colorectal cancers into new therapeutic strategies and surveillance methods, this genetic information unquestionably will be the springboard for determining what will be useful clinically against colorectal cancers,” said Harold Varmus, NCI director.

Abstract 3511. Identification and validation of gene expression subtypes in a large set

of colorectal cancer samples

J Clin Oncol 30, 2012 (suppl; abstr 3511)

PETACC3 + public datasets

Sabine Tejpar

Novel Subtypes are Characterized by Distinct Biological Components that Predict Patient Survival

Subtypes are Validated in Independent Datasets

Based on the set of gene modules derived , we performed subtype derivation in the validation set.

While subtypes A, C, D and E appeared in theLarger datasets are needed to confirm and further study additional subtypes.

Subtype SummaryA – normal -like epithelial: KRAS, differentiated, no CSC markers, Wnt down, good OS and RFS

B – proliferative epithelial: differentiated, but lost secretory cells, proliferative, 20q genes up, Wnt active, MSS, nonBRAF, non-mucinous, good OS, RFS, SAR

C – CIMP-H like: undifferentiated carcinomas, MSI, BRAF, mucinous, right, less frequently p53 mutated, enriched in females, proliferative, immune, CIMP+, the shortest SAR, poor OS

D – mesenchymal: no proliferation, high CSC markers, Wnt inactive, active EMT, the shortest RFS, poor OS and SAR

E – intermediate: MSS, nonBRAF, non mucinous, left, CSC markers, EMT, proliferation, differentiation, p53 enriched

Prevention

Charles Fuchs

Jeff Mayerhardt

Robert Sandler

John Baron

Colorectal Cancer: Risk Factors Overview

Decrease Risk Increase Risk Uncertain Impact

Screening Family history Statins

Exercise Aspirin / NSAIDs

Ulcerative colitis/ Crohn’s Disease

Fiber Glycemic load

Vitamin D Diabetes Fruits/Vegetables

Post-menopausal estrogen

Obesity Red meat

Folic Acid

Calcium Western diet

Alcohol

Smoking

Data from Observational Studies for Stage I-III Disease

Decrease risk of recurrence Physical activity Avoidance of Western pattern diet Avoidance of class II/ III obesity (BMI > 35 kg/m2) Aspirin or COX-2 inhibitor Higher vitamin D levels

No association with recurrence to date Weight change (gain or loss) Smoking status or history Multivitamin

Credits:Charles FuchsJeffrey MeyerhardtBrian WolpinKimmie NgAndrew ChanNadine McClearyDonna NiedzwieckiDonna HollisCALGB

Physical Activity and Colorectal Cancer

Cohort study from Australia of 526 colorectal cancer patients with pre-diagnosis physical activity assessment

Colorectal cancer specific survival

Haydon Gut. 2006 Jan;55(1):62-7

Van Loon K, Wigler D, Niedzwiecki D, Venook AP, Fuchs C, Blanke C, Saltz L, Goldberg RM, Meyerhardt JA, Clin Colorectal Cancer. Epub ahead of print 1/11/ 2013

89803 and Exercise: Disease-Free Survivalin Stage III Colon Cancer Survivors

Meyerhardt, J. A. et al. J Clin Oncol; 24:3535-3541 2006

Regular Physical Activity (met-hours per week)

<3 3-8.9 9-17.9 18.0-26.9 >270

Chart Title

NSABP and Body Mass Index

Dignam, J. J. et al. J. Natl. Cancer Inst. 2006 98:1647-1654

Disease-free and overall survival by body mass index (BMI) category in 4288 patients from National Surgical Adjuvant Breast and Bowel Project randomized clinical trials for

Dukes B and C colon cancer

Glycemic Loadin Colon Cancer Patients

Quintiles of Glycemic Load

tio fo

Meyerhardt, J. et al JNCI 2012

1 2 3 4 50

0.650000000000001

1 0.99 1.07

BMI < 25

Meyerhardt JA Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Natl Cancer Inst.104:1702-11, 2012.

Mortality among Patients with Colorectal Cancer, According to Regular Use or Nonuse of Aspirin after Diagnosis and PIK3CA

Mutation Status.

Liao X et al. N Engl J Med 367:1596-1606, 2012.

Screening

Colonoscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer

DeathsZauber A, Winawer SJ, O’Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, Shi W, Bond JH, Schapiro M,

Panish JF, Stewart ET, and Waye JD.

N Engl J Med 366:687-96, 2012.

Ann Zauber

National Polyp Study

2602 patients with adenomas removed between 1980-90.

CRC deaths expected: 25.4 CRC deaths observed: 12 53% reduction in mortality

These findings support the hypothesis that colonoscopic removal of adenomatous polyps prevents death from colorectal cancer.

DNA Stool Tests and CT Colonography

Perry Pickhardt

Ahlquist DA, Zou H, Domanico M, Mahoney DW, Yab TC, Taylor WR, Butz ML, Thibodeau SN, Rabeneck L, Paszat LF, Kinzler KW, Vogelstein B, BjerregaardNC, Laurberg S, Sørensen HT, Berger BM, Lidgard GP. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology. 142:248-56, 2012

Pickhardt PJ, Choi JR, Hwang I, Butler JA, Puckett ML, Hildebrandt HA, Wong RK, Nugent PA, Mysliwiec PA, Schindler WR. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults.N Engl J Med. 349:2191-200, 2003.

Stool DNA Testing

Biologically rational Noninvasive No cathartic preparation No diet or med restriction Off-site collection Widely accessible Not affected by lesion site High sensitivity for both CRC & precancer

Adenoma

Normal

Mucus at Cancer Surface

Arthur G. James Cancer Hospital and Richard J. Solove Research Institute 37

Detection Rates at 90% Specificity Cutoffs

Training Set Test Set Combined Set0

63.9 63.6 63.8

CRCAdenoma >1cm

Covariateanalysis

CT Colonography:Advanced Adenoma

Polyp size 10 mm or >. Prevalence c.5 -7 %

CT Colonography: Issues

Sensitivity: Detection of patients withadenomas >9mm:

Sensitivity SpecificityPickhardt 94% 96%Cotton 55% 96%Rockey 59% 96%

NEJM 2003; 349: 2191; JAMA 2004; 291:1713-9; Rockey: Lancet 2005;365: 305-11

Surgical Techniques

Laparoscopic Robotic

Laparoscopically Assisted Versus Open Colectomy For

Colon Cancer

Conventional Colectomy

Laparoscopic Colectomy (LAC)

790 patients accrued

Heidi NelsonN Engl J Med 351:933-934, 2004

COST Outcomes

Conversion rate

IncisionCm

TimeMinutes

LOSDays

IV narcsDays

PO narcsdays

LAC 21% 6 150 5 3 1

Open NA 18 95 6 4 2

P-value <.001 <.001 <.001 <.001 <.02

LAC vs Open Colectomy

No difference in Complication rate

Wound recurrences 30 day mortality (4 open, 2 LAC) Disease free survival Overall survival

Equivalent cancer procedures

Weeks, JAMA 2002Nelson, NEJM 2004

Other Effects

Eligible pt with stage II-IIIprimary rectal adenocarcinoma

by ERUS or MRI staging

Laparoscopicrectal resection

Openrectal resection

Randomization

Z6051: Lap Rectal Cancer TrialRectal Cancer

TME: a comparison of oncological and functional outcomes between robotic and

laparoscopic surgery for rectal cancer.

# Pts Time min

Med # nodes

Margin < 2 mm

Efficacy

Robotic 50 270 16.5 0 ?

Laparoscopic 50 275 13.8 6 ?

D'Annibale A, Pernazza G, Monsellato I, Pende V, Lucandri G, Mazzocchi P, Alfano G. Surg Endosc. Epub ahead of print, Jan 5, 2013

Liver ResectionGross Anatomy Eight Segments

Rene Adam

Survival After Liver Resection In Metastatic Colorectal Cancer: Review And Meta-analysis Of Prognostic Factors

3-yr survival (%)

5-yr survival (%)

Median survival

All 58% 40% 3.6 yearsSolitary 61 47 3.6

Extrahepatic 40 24 3.6

Isolated 54 39 3.2

Periop chemo 55 37 3.3

Resectable at Dx 55 41 3.3

Synchronous 46 37 3.2

Metachronous 58 43 3.3

Kanas GP, Taylor A, Primrose JN, Langeberg W, Kelsh MA, Mowat FS,Alexander DD, Choti MA, and Poston G. Clin Epidemiol. 4: 283–301, 2012.

SteatosisSinusoidal Dilatation

Steatohepatitis(NASH)

Types of Chemotherapy-Induced Hepatic Injury

Stereotactic body radiotherapy for colorectal liver metastases

Chang AT, Swaminath A, Kozak M, Weintraub J,Koong AC, John Kim J, Dinniwell R, Brierley J, Kavanagh BD, Dawson LA, Schefter TE. Cancer 117:4060–4069, 2011

Steriotactic Radiosurgery

47 patients Median dose: 42 Gray 3 fraction model 1 year local control 92%

Daniel Chang

Preoperative versus PostoperativeChemoradiotherapy for Rectal Cancer

Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens J-H, Liersch T, Schmidberger H, and

Raab R for the German Rectal Cancer Study Group

Locally advanced rectal cancer Radiation pre vs post operatively 5-FU chemotherapy TME 823 pts randomized Median follow up now 10 years

N Engl J Med 351:1731-174, 2004.J Clin Oncol. 30:1926-33, 2012

Cumulative Incidence of Local RelapseMedian Follow-up: 40 months

6050403020100

Months

p = 0.006

Post-op CRT

Pre-op CRT

German Rectal Cancer Trial

Preop Post op P-value

Pelvic recur 6% 12% 0.006

Distant recur 29.8% 29.6% 0.90

Survival 59.6% 59.9% 0.9

Gr 3-4 tox 29% 32% N.S.

Anastomotic stenosis 2.7% 8.5% 0.001

APR 39% 19% 0.004

Advances in the Drug Treatment of CRC

1980 1985 1990 1995 2000 2005

Therapeutic conceptsPalliative chemotherapy

Adjuvant chemotherapy

Neoadjuvant chemotherapy

CapecitabineOxaliplatin

CetuximabBevacizumab

Irinotecan5-FU

Updated from Kelly and Goldberg. J Clin Oncol. 2005;23:4553

AfliberceptRegorafinib

Hanna Kelly Sanoff

Oxaliplatin Vs 5-FU/LV In Adjuvant Therapy

MOSAIC & NSABP C-07

Aimery de Gramont Thierry Andre Greg Yothers Norman Wolmark

André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer: MOSAIC Investigators. N Engl J Med 350: 2343–51, 2004.

Yothers G, O'Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: Updated results of NSABP C-07, including survival and subset analyses. J Clin Oncol 29:3768–74, 2011.

MOSAIC Phase III Trial

RANDOMI

Z ATION

LV5FU2LV5FU2

FOLFOX4FOLFOX4N=1100

N=1100

• 40% Stage II

• 60% Stage III

Disease-free Survival: Stage II and III Patients

FOLFOX4 stage II

LV5FU2 stage II

FOLFOX4 stage III

LV5FU2 stage III

Months

0 6 12 18 24 6030 36 42 48 54 66 72

p=0.258

p=0.005

MOSAIC OS with >6 Years Follow-up

FOLFOX4 stage II

LV5FU2 stage II

FOLFOX4 stage III

LV5FU2 stage III

Overall survival (months)

0 6 12 18 24 6030 36 42 48 54 66 9672 78 84 90

p=0.996

p=0.029

NSABP C-07

Stage ll + lll

FLOXFU/LV

Randomize

Stratify: # positive nodes

Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses.

3-year DFS (stage III)Study treatment 3-year

Moertel Observation 52%

IMPACT Observation 44%

IMPACT 5FU/LV 62%

Punt 5FU/LV 65%

Fields 5FU/LV 67%

André 5FU/LV 61%

MOSAIC 5FU/LV 65%

X-Act Capecitabine 64%

MOSAICC-07

FOLFOX4FLOX

73%76%

2 drugs

Advances In Treatment Of Advanced Disease Since 2013

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S., Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F.Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer, N Engl J Med 350:2335-2342, 2004.

Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanthan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SA. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30, 2004.

FOLFOX4: oxaliplatin + infusional 5-FU/LV

IFL: irinotecan + bolus

5-FU/LV

IROX: oxaliplatin + irinotecan

Intergroup Study N9741: A Combination Chemotherapy Comparison

RANDOMIZATION

IFL (median 15.0 mo)FOLFOX4 (median 19.5 mo)IROX (median 17.4 mo)

FOLFOX4 vs IFL P=0.0001; HR=0.66

IROX vs IFL P=0.04; HR=0.81

FOLFOX4 vs IROX P=0.09; HR=0.830

Phase III Trial of Bevacizumab in First Line MCRC

IFL + placebo (n=411)

5-FU/LV + bevacizumab*(5 mg/kg, q2w) (n=110)

IFL + bevacizumab (5 mg/kg, q2w) (n=402)

RANDOMIZATION

Median Survival (mo)

IFL + placebo = 15.1IFL + bevacizumab = 20.55-FU/LV + bevacizumab =

Months

250 10 30 400

Treatment GroupIFL + placebo (n=101)*IFL + bevacizumab (n=103)*5-FU/LV + bevacizumab (n=110)

Cetuximab and Panitumumab

Cetuximab for the Treatment of Colorectal CancerJonker DJ, O'Callaghan CJ, Karapetis C, Zalcberg JR, Tu D, Au H-J, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R,Langer C, and Moore MJ. N Engl J Med 2007; 357:2040-2048

Van Cutsem E, Peeters M, Salvatore Siena S, Humble Y, Hendlisz A, Neyns B, Canon J-L, Van Laethem J-L, Maurel J, Richardson G, Wolf M, and Amado RG. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care ComparedWith Best Supportive Care Alone in Patients With Chemotherapy-RefractoryMetastatic Colorectal Cancer, J Clin Oncol. 25:1658-1664, 2007.

Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-1634.

Single Agent Cetuximab

RANDOMI ZE

Cetuximab* + BSC

BSC alone

Kaplan–Meier Curves for Progression-free Survival According to Treatment.

Karapetis CS et al. N Engl J Med 2008;359:1757-1765.

Progression Free Survival with Cetuximab aloneCorrelated with K-ras Status

Single Agent Panitumumab

RANDOMI ZE

Panitumumab + BSC

BSC alone

Single Agent Panitumumab: N=208

K-Ras Mutation Wild-Type K-Ras

Panitumumab registration trial

Aflibercept and Regorafinib

Grothey A, Cutsem EV, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D; for the CORRECT Study Group.Regorafenib monotherapy for previously treatedmetastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. Epub Nov 21 2012.

Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C. Addition Of Aflibercept To Fluorouracil, Leucovorin, And Irinotecan Improves Survival In A Phase III Randomized Trial In Patients With Metastatic Colorectal Cancer Previously Treated With An Oxaliplatin-based Regimen.J Clin Oncol. 30:3499-506, 2012.

600 ptsAflibercept 4 mg/kg IV+ FOLFIRI

600 ptsPlacebo + FOLFIRI

FOLFIRI +/- Aflibercept

Regorafinib

505 pts Regorafinib po+ BSC

255 ptsPlacebo + BSC

Regorafenib Cetuximab Panitumumab

Progression-Free Survival

median overall survival

Advances in the Treatment of Stage IV CRC

1980 1985 1990 1995 2000 2005

5-FUIrinotecan

CapecitabineOxaliplatin

CetuximabBevacizumab

Panitumumab

20152010

Aflibercept

Regorafenib

Guidelines:

Association Between Adherence To National Comprehensive Cancer

Network Treatment Guidelines And Improved Survival In Patients With

Colon Cancer.Boland GM, Chang GJ, Haynes AB, Chiang YJ, Chagpar R, Xing Y, Hu CY, Feig BW, You YN, Cormier JN. Cancer. Epub ahead of print Dec 21, 2012

Janice Cormier

Guidelines

Adjuvant Therapy of Colon Cancer

National Cancer Database 1998-2002 High risk Stage II and Stage III 167,434 patients Rates of guideline adherence

36% for high-risk stage II 74% Stage III

5-year survival versus adherence to guidelines Yes: 67.7% No: 54.5%

A Decade of Progress

Declining mortality by > 10% Potential for universal Lynch Syndrome screening Unraveling the mysteries of the genome Prevention & prevention of recurrence New screening tools: fecal DNA, CT colonography Laparoscopic, robotic and hepatic surgery Preoperative rectal radiation and Cyberknife Oxaliplatin, bevacizumab, cetuximab, panitumumab,

aflibercept, regorafinib

Fight Colorectal CancerCONTACT US

Fight Colorectal Cancer1414 Prince Street, Suite 204

Alexandria, VA 22314(703) 548-1225

Toll-Free Answer Line: 1-877-427-2111www.FightColorectalCancer.org

Email us: Info@FightColorectalCancer.org

The Latest in Colorectal Cancer Research

Health & Medicine

Transcript of The Latest in Colorectal Cancer Research

Colorectal Cancer - nlchi.nl.ca · Colorectal Cancer Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer death in Canada. Newfoundland

Colorectal Cancer in Europe - Mercuric · Colorectal Cancer in Europe A Framework for Improving Outcomes for Patients 7 Understanding colorectal cancer Colorectal cancer (CRC) is

Colorectal cancer review FINAL 112010phi.uhce.ox.ac.uk/pdf/CancerReviews/PROMs_Oxford...Colorectal Cancer Colorectal cancer, also known as colon/rectal/large bowel cancer, includes

Colorectal Cancer: Basic Fact Sheet Spanish · Colorectal Cancer: Basic Fact Sheet Spanish Author: Center for Disease Control and Prevention Subject: Colorectal Cancer Keywords: Colorectal

Colorectal or bowel cancer - SearchTheLibrary · Colorectal or bowel cancer. What is colorectal or bowel cancer? Colorectal cancer is a malignant (spreading) tumour that affects the

Colorectal Cancer

Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Colorectal Cancer Screening

Pattern of Comorbidities among Colorectal Cancer Patients in Spain · 2019-05-15 · Background Colorectal Cancer Colorectal cancer (CRC) was the most frequently diagnosed cancer

Colorectal cancer - The Most Important Questions...colorectal cancer. About 1,700 people die each year as a consequence of this illness. What causes colorectal cancer? Most colorectal

A GUIDE TO UNDERSTANDING COLORECTAL CANCER …...colorectal cancer; ultimately resulting in the empowerment of colorectal cancer patients and families during their cancer journey.

American Cancer Society Colorectal Cancer Survivorship Care Guidelines · guidelines. American Cancer Society Colorectal Cancer Survivorship Care Guidelines

Cancer Colorectal

Colorectal Cancer Awareness Infographic and Article · Colorectal cancer is the cause of CANCER DEATH in Nebraska The American Cancer Society estimates 840 new colorectal cancer cases

Colorectal Cancer Facts & Figures 2020-2022 · Colorectal Cancer Facts& Figures 2020-2022 1 Colorectal Cancer Basic Facts What is colorectal cancer? Cancer is a disease characterized

Colorectal Cancer Screeningnccrt.org/wp-content/uploads/CRCToolboxSlideSet_2009.pdf · Colorectal Cancer Screening and ... Colorectal Cancer Risk Factors Age ... • Family history

Colorectal Cancer. Summary: Content of Colorectal Cancer Tutorial Statistics Anatomy of the gastrointestinal tract Colorectal cancer Cancer progression.

Virtual Colonoscopy Colorectal Cancer Screening Saves Lives · 2014. 10. 13. · Colorectal Cancer Screening Saves Lives. Colorectal cancer is the second leading cancer killer—but

Colorectal Cancer Survivorship - MD Anderson … Cancer... · Colorectal Cancer Survivorship: Evaluation of Inherited Colorectal Cancer Risk ... Jeghers, la poliposis juvenil y la

colorectal cancer lecture